Lifecore Biomedical, Inc. LFCR
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 09/30/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -301.20% | -436.70% | -1.43% | 38.44% | 38.44% |
| Total Depreciation and Amortization | 21.66% | 31.40% | 11.27% | -0.60% | -0.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 327.85% | 78.06% | -27.20% | 49.08% | 49.08% |
| Change in Net Operating Assets | 768.34% | -731.38% | 324.55% | -91.46% | -91.46% |
| Cash from Operations | 294.21% | -140.94% | 291.67% | 374.03% | 374.03% |
| Capital Expenditure | 47.50% | 75.54% | 79.51% | 48.79% | 48.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 47.50% | 75.54% | -172.41% | 48.79% | 48.79% |
| Total Debt Issued | 200.83% | -78.22% | -- | 532.18% | 532.18% |
| Total Debt Repaid | -195.17% | 78.10% | -484.18% | -5,192.70% | -5,192.70% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 99.91% | -259.06% | -- | -96.26% | -96.26% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 74.41% | 41.15% | -- | -- |
| Cash from Financing | 82.71% | -111.94% | 96.23% | -226.99% | -226.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 525.09% | -224.79% | 182.37% | 53.67% | 53.67% |